tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Cautious Neutral Rating for Edgewise Therapeutics Amid Clinical and Regulatory Uncertainties
PremiumRatingsCautious Neutral Rating for Edgewise Therapeutics Amid Clinical and Regulatory Uncertainties
1M ago
Goldman Sachs assigns Neutral rating to Edgewise Therapeutics
Premium
The Fly
Goldman Sachs assigns Neutral rating to Edgewise Therapeutics
1M ago
Edgewise Therapeutics downgraded to Neutral from Buy at Goldman Sachs
Premium
The Fly
Edgewise Therapeutics downgraded to Neutral from Buy at Goldman Sachs
1M ago
Peloton upgraded, Booking downgraded: Wall Street’s top analyst calls
PremiumThe FlyPeloton upgraded, Booking downgraded: Wall Street’s top analyst calls
3M ago
3 Best Stocks to Buy Now, 7/30/2025, According to Top Analysts
Premium
Market News
3 Best Stocks to Buy Now, 7/30/2025, According to Top Analysts
3M ago
Edgewise Therapeutics initiated with a Strong Buy at Raymond James
Premium
The Fly
Edgewise Therapeutics initiated with a Strong Buy at Raymond James
3M ago
Edgewise update in line with expectations, says Leerink
PremiumThe FlyEdgewise update in line with expectations, says Leerink
4M ago
Truist sees ‘slight weakness’ for Edgewise Therapeutics on regulatory feedback
Premium
The Fly
Truist sees ‘slight weakness’ for Edgewise Therapeutics on regulatory feedback
4M ago
Promising Developments in Edgewise Therapeutics: A Buying Opportunity Amidst Regulatory Challenges
Premium
Ratings
Promising Developments in Edgewise Therapeutics: A Buying Opportunity Amidst Regulatory Challenges
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100